MONTPELLIER, France– SeqOne, a pioneer in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK genomics company spun out of the Wellcome Sanger Institute. The acquisition creates the largest global “software pure player” in clinical genomics, serving more than 160 laboratories across 30 countries. Terms of the deal were not disclosed.
Founded in 2012, Congenica has established a strong clinical reputation, supporting over 25 private and public labs, including NHS Genomics Laboratory Hubs and national programs such as Genomics England and the Hong Kong Genomic Program. SeqOne’s AI-powered platform delivers decision-support tools for oncology, rare and inherited diseases, and infectious diseases. Together, the companies aim to provide fast, accurate, and scalable interpretation of genomic data to accelerate rare disease diagnosis and enable more precise cancer therapies.
“The rapid pace of personalized medicine demands continuous investment in software innovation and deep specialization,” said Martin Dubuc, CEO of SeqOne. “By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market — a global leader in clinical genomics since the landmark 100,000 Genomes Project.”
The acquisition follows a period of rapid expansion for SeqOne, which doubled revenue and grew its international footprint from three to more than 30 countries in the past year. The company also recently acquired Life & Soft, expanding into multi-omics and virology, and raised €20 million from leading venture capital firms to accelerate its consolidation strategy in the genomics software space.
The combined entity will serve over 160 laboratories in more than 30 countries, employ 125 staff, and enable more than 200,000 patient genomic analyses in 2025 — triple the 2024 volume. SeqOne will maintain a UK presence at the Wellcome Sanger Institute to ensure continuity for Congenica customers.
“Congenica has been an instrumental partner to Genomics England, particularly in advancing rare disease diagnosis through their robust platform for clinical whole genome analysis,” said Dr. Richard Scott, Chief Executive Officer at Genomics England. “We look forward to continuing this important work with the combined expertise of the SeqOne team to deliver benefits for patients.”
“The Board of Congenica is proud of the immense impact our technology has had on healthcare since our inception,” said Dr. Andy Richards, CBE, Chairman of Congenica. “We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally.”
